Treatment and Management of ATTR: Understanding Small Interfering RNA and Emerging Therapies in the Treatment Landscape | PTCE Pharmacy Connect
Educational Objectives
•Review the clinical and economic burdens associated with transthyretin amyloidosis (ATTR)
•Recall key characteristics supporting the use of current and emerging therapies for the treatment of ATTR including mechanisms of action, clinical data, dosing, administration, and potential adverse effects
Faculty:
Svetlana Goldman, PharmD, BCACP, CDCES
Clinical Pharmacist
UC Davis Health
Sacramento, California
Yvette Hellier, PharmD, BCACP
Clinical Pharmacist
UC Davis Health
Sacramento, California
The following contributors have no relevant financial relationships with commercial interests to disclose:
Faculty
Svetlana Goldman, PharmD, BCACP, CDCES, and Yvette Hellier, PharmD, BCACP
Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 0.75 contact hour (0.075 CEU) under the ACPE universal activity number 0290-0000-22-045-H01-P. The activity is available for CE credit through February 28, 2023.
This activity is supported by an educational grant from Alnylam Pharmaceuticals.
Learn more about your ad choices. Visit megaphone.fm/adchoices
•Review the clinical and economic burdens associated with transthyretin amyloidosis (ATTR)
•Recall key characteristics supporting the use of current and emerging therapies for the treatment of ATTR including mechanisms of action, clinical data, dosing, administration, and potential adverse effects
Faculty:
Svetlana Goldman, PharmD, BCACP, CDCES
Clinical Pharmacist
UC Davis Health
Sacramento, California
Yvette Hellier, PharmD, BCACP
Clinical Pharmacist
UC Davis Health
Sacramento, California
The following contributors have no relevant financial relationships with commercial interests to disclose:
Faculty
Svetlana Goldman, PharmD, BCACP, CDCES, and Yvette Hellier, PharmD, BCACP
Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 0.75 contact hour (0.075 CEU) under the ACPE universal activity number 0290-0000-22-045-H01-P. The activity is available for CE credit through February 28, 2023.
This activity is supported by an educational grant from Alnylam Pharmaceuticals.
Learn more about your ad choices. Visit megaphone.fm/adchoices
Activity